-
Je něco špatně v tomto záznamu ?
Outcomes from the International Society of Nephrology Hemolytic Uremic Syndromes International Forum
D. Kavanagh, G. Ardissino, V. Brocklebank, RN. Bouwmeester, A. Bagga, R. Ter Heine, S. Johnson, C. Licht, ALT. Ma, M. Noris, M. Praga, E. Rondeau, A. Sinha, RJH. Smith, NS. Sheerin, H. Trimarchi, JFM. Wetzels, M. Vivarelli, NCAJ. Van de Kar, LA....
Jazyk angličtina Země Spojené státy americké
Typ dokumentu časopisecké články
NLK
Freely Accessible Science Journals
od 1972
Open Access Digital Library
od 1972-01-01
- MeSH
- atypický hemolyticko-uremický syndrom genetika imunologie terapie farmakoterapie diagnóza MeSH
- biologické markery krev MeSH
- hemolyticko-uremický syndrom * terapie imunologie diagnóza MeSH
- inhibitory komplementu terapeutické užití MeSH
- komplement imunologie MeSH
- lidé MeSH
- nefrologie * normy metody MeSH
- společnosti lékařské normy MeSH
- transplantace ledvin škodlivé účinky MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
Hemolytic uremic syndromes (HUSs) are a heterogeneous group of conditions, only some of which are mediated by complement (complement-mediated HUS). We report the outcome of the 2023 International Society of Nephrology HUS International Forum where a global panel of experts considered the current state of the art, identified areas of uncertainty, and proposed optimal solutions. Areas of uncertainty and areas for future research included the nomenclature of HUS, novel complement testing strategies, identification of biomarkers, genetic predisposition to atypical HUS, optimal dosing and withdrawal strategies for C5 inhibitors, treatment of kidney transplant recipients, disparity of access to treatment, and the next generation of complement inhibitors in complement-mediated HUS. The current rationale for optimal patient management is described.
Center for Hemolytic Uremic Syndrome Ca' Granda Ospedale Maggiore Policlinico Milan Italy
Department of Nephrology Instituto de Investigación Hospital 12 de Octubre Madrid Spain
Department of Pediatrics and Adolescent Medicine The University of Hong Kong Hong Kong China
Department of Pharmacy Radboud University Medical Center Nijmegen The Netherlands
Division of Nephrology Laboratory of Nephrology Bambino Gesù Children's Hospital IRCCS Rome Italy
Division of Nephrology The Hospital for Sick Children University of Toronto Toronto Ontario Canada
Medicine Department Universidad Complutense de Madrid Madrid Spain
Molecular Otolaryngology and Renal Research Laboratories The University of Iowa Iowa City Iowa USA
Nephrology Service Hospital Britanico de Buenos Aires Buenos Aires Argentina
Paediatric Nephrology Centre Hong Kong Children's Hospital Hong Kong China
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc25003225
- 003
- CZ-PrNML
- 005
- 20250206104201.0
- 007
- ta
- 008
- 250121s2024 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.kint.2024.09.012 $2 doi
- 035 __
- $a (PubMed)39395628
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Kavanagh, David $u National Renal Complement Therapeutics Centre, Newcastle upon Tyne Hospitals National Health Service Foundation Trust, Newcastle upon Tyne, United Kingdom; Complement Therapeutics Research Group, Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, United Kingdom. Electronic address: david.kavanagh@ncl.ac.uk
- 245 10
- $a Outcomes from the International Society of Nephrology Hemolytic Uremic Syndromes International Forum / $c D. Kavanagh, G. Ardissino, V. Brocklebank, RN. Bouwmeester, A. Bagga, R. Ter Heine, S. Johnson, C. Licht, ALT. Ma, M. Noris, M. Praga, E. Rondeau, A. Sinha, RJH. Smith, NS. Sheerin, H. Trimarchi, JFM. Wetzels, M. Vivarelli, NCAJ. Van de Kar, LA. Greenbaum, Forum Participants
- 520 9_
- $a Hemolytic uremic syndromes (HUSs) are a heterogeneous group of conditions, only some of which are mediated by complement (complement-mediated HUS). We report the outcome of the 2023 International Society of Nephrology HUS International Forum where a global panel of experts considered the current state of the art, identified areas of uncertainty, and proposed optimal solutions. Areas of uncertainty and areas for future research included the nomenclature of HUS, novel complement testing strategies, identification of biomarkers, genetic predisposition to atypical HUS, optimal dosing and withdrawal strategies for C5 inhibitors, treatment of kidney transplant recipients, disparity of access to treatment, and the next generation of complement inhibitors in complement-mediated HUS. The current rationale for optimal patient management is described.
- 650 _2
- $a lidé $7 D006801
- 650 12
- $a nefrologie $x normy $x metody $7 D009398
- 650 12
- $a hemolyticko-uremický syndrom $x terapie $x imunologie $x diagnóza $7 D006463
- 650 _2
- $a transplantace ledvin $x škodlivé účinky $7 D016030
- 650 _2
- $a komplement $x imunologie $7 D003165
- 650 _2
- $a inhibitory komplementu $x terapeutické užití $7 D051056
- 650 _2
- $a biologické markery $x krev $7 D015415
- 650 _2
- $a společnosti lékařské $x normy $7 D012955
- 650 _2
- $a atypický hemolyticko-uremický syndrom $x genetika $x imunologie $x terapie $x farmakoterapie $x diagnóza $7 D065766
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Ardissino, Gianluigi $u Center for Hemolytic Uremic Syndrome (HUS) Prevention, Pediatric Nephrology, Dialysis and Transplantation Unit, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Ca' Granda, Ospedale Maggiore Policlinico, Milan, Italy
- 700 1_
- $a Brocklebank, Vicky $u National Renal Complement Therapeutics Centre, Newcastle upon Tyne Hospitals National Health Service Foundation Trust, Newcastle upon Tyne, United Kingdom; Complement Therapeutics Research Group, Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, United Kingdom
- 700 1_
- $a Bouwmeester, Romy N $u Radboud University Medical Center, Amalia Children's Hospital, Radboud Institute for Molecular Life Sciences, Department of Pediatric Nephrology, Nijmegen, The Netherlands
- 700 1_
- $a Bagga, Arvind $u Division of Nephrology, Department of Pediatrics, All India Institute of Medical Sciences, New Delhi, India
- 700 1_
- $a Ter Heine, Rob $u Department of Pharmacy, Radboud University Medical Center, Nijmegen, The Netherlands
- 700 1_
- $a Johnson, Sally $u National Renal Complement Therapeutics Centre, Newcastle upon Tyne Hospitals National Health Service Foundation Trust, Newcastle upon Tyne, United Kingdom; Great North Children's Hospital, Sir James Spence Institute, Royal Victoria Infirmary, Newcastle upon Tyne, United Kingdom
- 700 1_
- $a Licht, Christoph $u Division of Nephrology, The Hospital for Sick Children, University of Toronto, Toronto, Ontario, Canada
- 700 1_
- $a Ma, Alison L T $u Paediatric Nephrology Centre, Hong Kong Children's Hospital, Hong Kong, China; Department of Pediatrics and Adolescent Medicine, The University of Hong Kong, Hong Kong, China
- 700 1_
- $a Noris, Marina $u Istituto di Ricerche Farmacologiche Mario Negri Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Clinical Research Center for Rare Diseases Aldo e Cele Daccò, Ranica, Italy
- 700 1_
- $a Praga, Manuel $u Department of Nephrology, Instituto de Investigación Hospital 12 de Octubre (imas12), Madrid, Spain; Medicine Department, Universidad Complutense de Madrid, Madrid, Spain
- 700 1_
- $a Rondeau, Eric $u Intensive Care Nephrology and Transplantation Department, Assistance Publique des Hôpitaux de Paris (AP-HP) - Sorbonne Université, Paris, France
- 700 1_
- $a Sinha, Aditi $u Division of Nephrology, Department of Pediatrics, All India Institute of Medical Sciences, New Delhi, India
- 700 1_
- $a Smith, Richard J H $u Molecular Otolaryngology and Renal Research Laboratories, The University of Iowa, Iowa City, Iowa, USA
- 700 1_
- $a Sheerin, Neil S $u National Renal Complement Therapeutics Centre, Newcastle upon Tyne Hospitals National Health Service Foundation Trust, Newcastle upon Tyne, United Kingdom; Complement Therapeutics Research Group, Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, United Kingdom
- 700 1_
- $a Trimarchi, H $u Nephrology Service, Hospital Britanico de Buenos Aires, Buenos Aires, Argentina
- 700 1_
- $a Wetzels, Jack F M $u Department of Nephrology, Radboud University Medical Center, Radboud Institute for Health Sciences, Nijmegen, The Netherlands
- 700 1_
- $a Vivarelli, Marina $u Division of Nephrology, Laboratory of Nephrology, Bambino Gesù Children's Hospital IRCCS, Rome, Italy
- 700 1_
- $a Van de Kar, Nicole C A J $u Radboud University Medical Center, Amalia Children's Hospital, Radboud Institute for Molecular Life Sciences, Department of Pediatric Nephrology, Nijmegen, The Netherlands
- 700 1_
- $a Greenbaum, Larry A $u Division of Pediatric Nephrology, Department of Pediatrics, Emory University School of Medicine, Atlanta, Georgia, USA. Electronic address: lgreen6@emory.edu
- 710 2_
- $a Forum Participants
- 773 0_
- $w MED00010141 $t Kidney international $x 1523-1755 $g Roč. 106, č. 6 (2024), s. 1038-1050
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/39395628 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20250121 $b ABA008
- 991 __
- $a 20250206104157 $b ABA008
- 999 __
- $a ok $b bmc $g 2263152 $s 1239232
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2024 $b 106 $c 6 $d 1038-1050 $e 20241010 $i 1523-1755 $m Kidney international $n Kidney Int $x MED00010141
- LZP __
- $a Pubmed-20250121
